Karyopharm Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKaryopharm Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 55% provides fundamental context to the price action. Investors should exercise caution due to high volatility (95% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.35 | +2.85% | ABOVE |
| 50 SMA | $8.95 | +7.44% | ABOVE |
| 100 SMA | $8.52 | +12.97% | ABOVE |
| 150 SMA | $7.92 | +21.50% | ABOVE |
| 200 SMA | $7.43 | +29.43% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KPTI in an uptrend right now?
KPTI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KPTI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KPTI overbought or oversold?
KPTI's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is KPTI outperforming the market?
KPTI has a Relative Strength (RS) Rating of 80 out of 99. Yes, KPTI is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is KPTI in its 52-week range?
KPTI is trading at $9.62, which is 88% of its 52-week high ($10.99) and 81% above its 52-week low ($3.65).
How volatile is KPTI?
KPTI has a Beta of 1.09 and 52-week volatility of 95%. It's more volatile than the S&P 500 - expect bigger swings.